NCT06719414 Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
| NCT ID | NCT06719414 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Condition | Rectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 320 participants |
| Start Date | 2024-10-22 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 320 participants in total. It began in 2024-10-22 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy. The main question it aims to answer is: • Does amide proton transfer-weighted imaging predict the cancer response before surgery? Participants will underwent amide proton transfer-weighted imaging as part of their regular MRI examination.
Eligibility Criteria
Inclusion Criteria: * Locally advanced rectal cancer(cT3-4, or cN+), resectable, histologically confirmed rectal adenocarcinoma * Received neoadjuvant therapy before surgery * Complete radical resection of rectal cancer and postoperative pathological examination * Informed consent and signed the informed consent form Exclusion Criteria: * Poor image quality, such as severe artifacts * Complicated with intestinal obstruction, intestinal perforation and other cases requiring surgical treatment * The interval between preoperative MRI and surgery was more than 2 weeks * Prior treatment for rectal cancer * History of other malignant tumors * Patients who cannot undergo MRI examination due to contraindications or relative contraindications * Patients were lost to follow-up or voluntarily withdrew from the study due to adverse reactions or other reasons
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06719414 clinical trial?
This trial is open to participants of all sexes, studying Rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06719414 currently recruiting?
Yes, NCT06719414 is actively recruiting participants. Contact the research team at xiepy6@mail.sysu.edu.cn for enrollment information.
Where is the NCT06719414 trial being conducted?
This trial is being conducted at Guangzhou, China, Maoming, China.
Who is sponsoring the NCT06719414 clinical trial?
NCT06719414 is sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. The trial plans to enroll 320 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.